Immune blockade of IL-6 is approved for use in autoimmune diseases with a substantial role in inflammation; a few anti-IL-6 therapies are currently in use for rheumatologic disease, yet there is a lack of studies in heart failure [96]. This evidence concerns the gene IL6 and autoimmune disease.